根据随机临床试验的资格,阿托匹克皮肤炎患者的特征,治疗和安全概况:西班牙阿托匹克皮肤炎注册表 (BIOBADATOP) 的分析
M Munera-Campos1, A González Quesada2, M Espasandín Arias3
1Departmentd of Dermatología, Hospital Universitari Germans Trias i Pujol, Departament de Medicina, Universitat Autonoma de Barcelona (UAB), Germans Trias i Pujol Research Institute (IGTP). Badalona, Barcelona, Spain.
Actas dermo-sifiliograficas
|December 4, 2025
概括
许多患有亚托皮性皮肤炎 (AD) 的成年人被排除在临床试验之外. 现实数据显示,这些患者在考虑年龄和并发症时具有相似的安全结果.
科学领域:
- 皮肤病学 皮肤病学
- 临床药理学 临床药理学
- 现实世界的证据 现实世界的证据
背景情况:
- 针对阿托皮性皮炎 (AD) 治疗的随机临床试验 (RCT) 经常使用严格的资格标准,限制了对更广泛患者群体的概括性.
- 这导致某些患者群体在试验结果中的潜在代表性不足.
研究的目的:
- 量化使用先进系统疗法治疗阿尔茨海默病的成年人中不符合RCT资格的比例.
- 为了在现实环境中比较这些疗法的安全性和药物存活率,在符合RCT条件的患者和不符合RCT条件的患者之间.
主要方法:
- 对接受先进全身治疗的成年人西班牙亚托皮炎登记 (BIOBADATOP) 的分析.
- 根据常见的排除标准 (例如年龄,并发症,特定健康状况) 将患者归类为不符合RCT资格的患者.
- 在符合条件和不符合条件的组之间,安全性和药物存活率进行了比较.
主要成果:
- 临床实践中的18.3%的患者不符合RCT的条件,如果考虑较低的EASI得分值,这一数字将上升到37.2%.
- 不符合条件的患者年龄较大,并患有更多的并发症.
- 虽然严重不良事件最初在不符合条件的患者中较高,但在调整人口统计和临床因素后,这种差异减少了.
结论:
- 在临床试验中,大量的真实世界皮炎患者在临床试验中代表性不足.
- 患者的年龄和并发症是影响治疗安全性的关键因素,应指导临床决策和未来试验设计.
相关概念视频
Clinical Trials
10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.1K
Bioavailability Study Design: Healthy Subjects Versus Patients
135
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
135
Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
382
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
382
Drug Products: Biologics, Biosimilars and Interchangeables
219
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
219
Dosage Regimens: Partial Pharmacokinetic Parameters
135
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
135


